Brought to you by 
Shire off-loads late-stage ASBT inhibitors to Mirum
Nov 2018
Executive Summary
Shire PLC licensed Mirum Pharmaceuticals exclusive global rights to the apical sodium dependent bile acid transporter inhibitors maralixibat (SHP625) and volixibat (SHP626).
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
- Includes Equity
- Reverse Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire off-loads late-stage ASBT inhibitors to Mirum
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice